Donald Jensen to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Donald Jensen has written about Dose-Response Relationship, Drug.
Connection Strength
0.217
-
Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report. Dig Dis Sci. 2009 Jun; 54(6):1369-72.
Score: 0.073
-
A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. J Clin Gastroenterol. 2003 Apr; 36(4):352-5.
Score: 0.050
-
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302.
Score: 0.028
-
Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opin Drug Saf. 2012 Nov; 11(6):901-9.
Score: 0.024
-
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol. 2012 Jan-Feb; 11(1):15-31.
Score: 0.023
-
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology. 2008 Oct; 48(4):1033-43.
Score: 0.018